Precision BioSciences(DTIL)

DURHAM, NCBiotechnology1 H-1B visas (FY2023)

Focus: Precision BioSciences is a publicly traded biotech company focused on genome-editing enzymes and CAR-T cell therapies, headquartered in Durham, NC. The company operates at mid-cap scale with significant R&D intensity but derives 99% revenue from a single generic antibiotic.

Cell Therapy

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Precision BioSciences

AI assessmentNot Hiring

No open roles listed right now. Follow Precision BioSciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$69M

Key Products

FOSFOMYCIN TROMETHAMINE

Pyelonephritis, perinephric abscess

$2M Part D

Post-LOE

Sole revenue driver ($69M FY2025) but generic antibiotic facing commoditization and pricing pressure; unsustainable as core business.

Help build intelligence for Precision BioSciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Watch Out For

Extreme revenue concentration (99% from single generic antibiotic) creates significant financial fragility and restructuring risk if generic pricing collapses
Zero active job openings reported despite aggressive pipeline suggests potential hiring freeze or portfolio misalignment with commercial needs
Early-stage pipeline (39 Phase 1, only 2 Phase 3) with no near-term approval catalysts means 5+ years before potential revenue diversification

Pipeline & Clinical Trials

Freedom SCS System

Back Pain

N/A

ClariCore System

Prostate Cancer

N/A

Clinical Trials (1)

NCT03734575ClariCore System Used in Transperineal Prostate Biopsy

N/A

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Perit

Ovarian Cancer

N/A

Clinical Trials (1)

NCT00288275Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

N/A

Phase 1 Wonderlab Product

Diabetes

N/A

Clinical Trials (1)

NCT05756712The Efficacy of White Kidney Bean on Oral Glucose Tolerance Test

N/A

Data Mining: Precision Analytical Retrospective Data Correlation

Obesity; Endocrine

N/A

Clinical Trials (1)

NCT04305093Data Mining: Precision Analytical Retrospective Data Correlation

N/A

Study product A

Overweight

N/A

Clinical Trials (1)

NCT05710055The Efficacy on Overweight With Oral Supplemenation of Probiotics and Prebiotics

N/A

EPIONE® CT-Guided Percutaneous procedures

Cancer Abdomen

N/A

Clinical Trials (1)

NCT05529979Epione® Post-Market Clinical Follow-up Study

N/A

Biological analysis, Physical examination and Questionnaires

Diabetes

N/A

Clinical Trials (1)

NCT05717491Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France

N/A

ChemoFx® PRO - A Post-Market Data Collection Study

Ovarian Cancer

N/A

Clinical Trials (1)

NCT00669422ChemoFx® PRO - A Post-Market Data Collection Study

N/A

Blood test: ClarityDX Prostate

Prostate Cancer

N/A

Clinical Trials (1)

NCT03957252Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

N/A

Phlebotomy

COVID-19

N/A

ChemoFx

Ovarian Cancer

N/A

Clinical Trials (1)

NCT01048814Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases

N/A

Exploring a Potential Blood Test to Diagnose Major Depressive Disorder

Major Depressive Disorder

N/A

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developme

SCN2A-DEE

N/A

Common Elements Toolbox

Depressive Symptoms

N/A

Clinical Trials (1)

NCT04815681Evaluating an Online Wellness Intervention for Greek Adolescents

N/A

VIVO™

Premature Ventricular Contraction

N/A

The Quantum Surgical device

Hepatic Tumor

N/A

Clinical Trials (1)

NCT04230642Multicenter Study to Evaluate a New Robotic Device for Image-guided Percutaneous Needle Placement

N/A

EPIONE device

Lung Cancer

N/A

Clinical Trials (1)

NCT05651867EPIONE Guided Lung Evaluation

N/A

MalariaSense device

Malaria

N/A

Clinical Trials (1)

NCT02672228Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense)

N/A

ClariCore Optical Biopsy System

Cellular Diagnosis, Prostate Cancer

N/A

Clinical Trials (1)

NCT03504761ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

N/A

Web-based CBT

Chronic Pancreatitis

N/A

Biobanking with genetic analysis

Chronic Inflammatory Disease

N/A

Clinical Trials (1)

NCT04334031Deployment o the Multidisciplinary Prospective Cohort Imminent

N/A

A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Solid Organ Tumors

N/A

Clinical Trials (1)

NCT01271959A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

N/A

mobile internet survey on self-test

Susceptibility to Viral and Mycobacterial Infection

N/A

Clinical Trials (1)

NCT04256395Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19

N/A

Wonderlab Kids instant probiotics

Immunity

N/A

Clinical Trials (1)

NCT05585021Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Improvement of Preschool Children

N/A

Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up

Breast Cancer Risk

N/A

Clinical Trials (1)

NCT05848856The RISC Registry--Risk Informed Screening Registry

N/A

DermaTherapy® Linen and underpads.

Pressure Ulcers

N/A

Clinical Trials (1)

NCT01355666Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting

N/A

Community Health Worker Support

Cancer

N/A

Clinical Trials (1)

NCT04843332Community Health Workers and Precision Medicine

N/A

Scleral lens wearing keratoconics

Keratoconus

N/A

Clinical Trials (1)

NCT03091101Impact of Scleral Contact Lens Wear on Corneal Nerves in Keratoconus

N/A

Custom Fabricated Splint

Arthritis

N/A

Clinical Trials (1)

NCT05351060Novel Splinting Technique Using 3D Models

N/A

DermaTherapy® Linen and underpads.

Pressure Ulcers

N/A

Clinical Trials (1)

NCT01403272Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting

N/A

Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring

Biliary Tract Cancer

N/A

Clinical Trials (1)

NCT04561453Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

N/A

Silk-Like Linens

Pressure Ulcer

N/A

Clinical Trials (1)

NCT02925741Silk-Like Bed Linens for Prevention of Unit-Acquired Ulcers

N/A

6 Minute Walk Test

Aged

N/A

Clinical Trials (1)

NCT03123757Assessing the Determinants of 6-minute Walk Test and Its Correlation With Quality of Life

N/A

Standardized assessments, guided tumor biopsy and biobanking

Decompensated Liver Cirrhosis

N/A

Clinical Trials (1)

NCT06723275LEOPARD Prospective Validation Cohort 1

N/A

Percutaneous procedure in the MSK structures of the pelvis and/or the spine

Bone Tumor

N/A

Clinical Trials (1)

NCT07325578U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures

N/A

CMV-VST

Cytomegalovirus Viremia

N/A

Clinical Trials (1)

NCT07015801CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

N/A

CT-guided bone percutaneous procedure

Bone Metastases

N/A

Clinical Trials (1)

NCT06376682EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy

N/A

mNGS for pathogen detection

Encephalitis

N/A

Optical coherence tomography

Optical Coherence Tomography

N/A

Clinical Trials (1)

NCT05517889Repeatability and Stability of Healthy Skin Features on OCT

N/A

Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease

Non-Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT01450553Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease

N/A

Gynaecological laparoscopic surgery

Ovarian Cancer

N/A

Clinical Trials (1)

NCT05048407Sirius in Gynaecological Laparoscopic Surgery

N/A

Silk like Pillowcase

Acne Vulgaris

N/A

Clinical Trials (1)

NCT00767104Efficacy of Silk - Like Bedding Fabric Pillow Case in the Treatment of Acne Vulgaris

N/A

VIVO

Ventricular Arrythmia

N/A

Chilean Gastric Cancer Task Force (FORCE 1)

Biomarkers

N/A

Clinical Trials (1)

NCT03158571Chilean Gastric Cancer Task Force (FORCE 1)

N/A

Education Program

Stress

N/A

detect HPV E7 ctDNA

Uterine Cervical Neoplasms

N/A

Clinical Trials (1)

NCT05531981Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer

N/A

CPMRx

Opioid Misuse

N/A

Clinical Trials (1)

NCT05461196Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section

N/A

Trio Whole Genome Sequencing and Participant-Specific Research

Rare Diseases

N/A

Mobile Health Monitoring

Hypertension

N/A

Clinical Trials (1)

NCT03349918PERsonal ContExtual Precision healTh

N/A

Interview Prep Quick Facts

Founded: 2021

Portfolio: 18 approved products, 134 clinical trials

Top TAs: Oncology, Immunology, Metabolic Diseases

H-1B (2023): 1 approval

Publications: 25 in PubMed

SEC Filings: 2 available

Portfolio Health

Pre-Launch3 (17%)

LOE Approaching2 (11%)

Post-LOE13 (72%)

18 total products

Therapeutic Area Focus

Oncology

94 pipeline

Immunology

10 marketed11 pipeline

Metabolic Diseases

6 pipeline

Infectious Diseases

1 marketed4 pipeline

Neurology

Financials (FY2025)

Revenue

$69M41%

R&D Spend

$60M(87%)12%

Net Income

$7M

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Transient muscle expression of mitoARCUS in mice leads to sustained reductions in pathogenic mtDNA and reduces fatigability.

Molecular therapy : the journal of the American Society of Gene Therapy

2025

PMID:41445195

RHO1-2 meganuclease gene editing targets human P23H rhodopsin-induced retinitis pigmentosa to rejuvenate rods and maintain cones.

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral administration. Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min.). This percentage excretion may fall as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min.). Studies have shown no significant difference in serum half-life of doxycycline (range 18-22 hours) in individuals with normal and severely impaired renal function. Hemodialysis does not alter serum half-life. Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues. Population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 pediatric patients (2-18 years of age) showed that allometrically -scaled clearance (CL) of doxycycline in pediatric patients ≥2 to ≤8 years of age (median [range] 3.58 [2.27-10.82] L/h/70 kg, N =11) did not differ significantly from pediatric patients >8 to 18 years of age (3 .27 [1.11-8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median [range] 0.071 [0 .041-0.202] L/kg/h, N=10) did not differ significantly from those >8 to 18 years of age (0.081 [0.035-0.126] L/kg/h, N=8). In pediatric patients weighing >45 kg, no clinically significant differences in body weight normalized doxycycline CL were observed between those ≥2 to ≤8 years (0.050 L/kg/h, N=l) and those >8 to 18 years of age (0.044 [0.014-0.121] L/kg/h, N=25). No clinically significant difference in CL between oral and IV dosing was observed in the small cohort of pediatric patients who received the oral (N=19) or IV (N=21) formulation alone. Microbiology Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Resistance Cross resistance with other tetracyclines is common. Antimicrobial Activity Doxycycline has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert for doxycycline hyclate tablets, USP. Gram-Negative Bacteria Acinetobacter species Bartonella bacilliformis Brucella species Klebsiella species Klebsiella granulomatis Campylobacter fetus Enterobacter aerogenes Escherichia coli Francisella tularensis Haemophilus ducrey

Precision BioSciences(DTIL)

About Precision BioSciences

Why Work Here

Key Products

Watch Out For

Products & Portfolio (7)

Key Products by Revenue

Other Products (6)

Pipeline & Clinical Trials

Recent News · Precision BioSciences(2)

Open Jobs (0)

Financials (FY2025)

Visa Sponsorship

Research Publications(10)